Cargando…
Ketamine’s antidepressant effect is mediated by energy metabolism and antioxidant defense system
Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently available antidepressants (ADs) show full remission. Moreover, about one third of the patients suffering from MDD does not respond to conventional ADs and develop treatment-resistant depression (TRD). Ketamine...
Autores principales: | Weckmann, Katja, Deery, Michael J., Howard, Julie A., Feret, Renata, Asara, John M., Dethloff, Frederik, Filiou, Michaela D., Iannace, Jamie, Labermaier, Christiana, Maccarrone, Giuseppina, Webhofer, Christian, Teplytska, Larysa, Lilley, Kathryn, Müller, Marianne B., Turck, Christoph W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694011/ https://www.ncbi.nlm.nih.gov/pubmed/29150633 http://dx.doi.org/10.1038/s41598-017-16183-x |
Ejemplares similares
-
Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates
por: Weckmann, K, et al.
Publicado: (2014) -
Behavioral and Metabolome Differences between C57BL/6 and DBA/2 Mouse Strains: Implications for Their Use as Models for Depression- and Anxiety-Like Phenotypes
por: Filiou, Michaela D., et al.
Publicado: (2021) -
Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans
por: Park, Dong Ik, et al.
Publicado: (2016) -
Multi-Omics Analysis Reveals Myelin, Presynaptic and Nicotinate Alterations in the Hippocampus of G72/G30 Transgenic Mice
por: Filiou, Michaela D., et al.
Publicado: (2022) -
Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems
por: Park, D I, et al.
Publicado: (2017)